Key recommendations center on biologic treatments, according to a May 27 news release. Biologic treatment should be used early, instead of waiting to see if other options fail, the guidelines suggest. The guidelines also say the biologic, natalizumab, is no longer recommended due to potential adverse side effects.
“We hope this new guideline serves as a manual for clinicians in selecting the right therapies for their patients, which should lead to improved patient outcomes and less need for invasive surgery,” lead author Joseph Feuerstein, MD, said.
Read the full guideline published in Gastroenterology here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.